Browse the evidence

Obesity-associated adipose tissue inflammation, driven by macrophage infiltration and cytokine release, directly blunts insulin signaling and contributes to systemic insulin resistance.

In obesity, fat tissue isn't just storage; it becomes inflamed, recruiting immune cells that block insulin's ability to work. Reducing this inflammation is key to improving metabolic health.

Adiponectin overexpression in adipose tissue improves metabolic profile and insulin sensitivity by promoting lipid storage in subcutaneous fat and reducing ectopic lipid accumulation.

Adiponectin helps store fat safely in subcutaneous tissue, preventing it from accumulating in organs like the liver and muscle, thereby protecting insulin sensitivity.

Adiposity (body fat percentage) does not significantly modify the acute or chronic appetite and energy intake responses to exercise, meaning exercise is equally effective for appetite regulation in lean and overweight/obese individuals.

Your body weight does not determine how well exercise works for regulating your appetite. Whether you are lean or have overweight/obesity, exercise will similarly suppress your appetite temporarily and not trigger compensatory overeating. This makes exercise a universally applicable tool for energy balance.

In insulin-resistant obese women, elevated intramyocellular triglyceride (IMTG) content is specifically associated with insulin resistance in Type I myocytes, whereas Type II myocytes show no such association despite similar or higher total lipid loads.

For older obese women, insulin resistance is not just about how much fat is stored in the muscle overall, but specifically where it is stored. High levels of a specific lipid called ceramide, found alongside IMTG in slow-twitch (Type I) muscle fibers, are strongly linked to insulin resistance. Fast-twitch (Type II) fibers did not show this link. This suggests that improving the health or proportion of slow-twitch fibers, or managing lipid metabolism specifically within them, may be key to improving insulin sensitivity.

Elevated ceramide content (both saturated and unsaturated) is significantly higher in insulin-resistant skeletal muscle, independent of obesity and physical fitness levels.

Insulin-resistant muscle contains significantly higher levels of ceramides, a type of fat molecule that interferes with insulin signaling. This elevation is seen even when comparing obese individuals with similar fitness levels, suggesting that ceramide accumulation is a key feature of insulin resistance itself, not just a byproduct of being overweight.

Low energy availability causes a 'sick euthyroid' profile with decreased T3 and increased reverse T3, reducing energy expenditure as an adaptive response.

Low energy intake can lower your T3 levels as a way to conserve energy. This is a normal adaptation, not necessarily a thyroid disease. Focus on eating enough to support your activity level, which should normalize your thyroid hormones.

Interindividual variability in triglyceride response to low-fat, high-carb diets is determined by the 24-hour pattern of fatty acid synthesis (constant vs. diurnal), not by body mass index or insulin levels.

Not everyone reacts to low-fat, high-carb diets with high triglycerides. Your response depends on whether your body maintains high fat synthesis constantly throughout the day or only spikes after meals. Those with 'constant' high synthesis have much higher triglycerides, regardless of their weight or insulin levels.

A reduced ratio of branched-chain amino acids (BCAA) to aromatic amino acids (AAA) in plasma is a specific metabolic signature of PCOS that is independent of obesity and insulin resistance, distinguishing it from type 2 diabetes profiles.

Your amino acid profile, specifically the balance between BCAA and AAA, is a unique fingerprint of PCOS. This helps doctors distinguish your condition from type 2 diabetes, even if you have insulin resistance. This distinction is important for tailoring the right treatment strategy for your specific metabolic needs.

Ovulatory dysfunction in PCOS is associated with elevated levels of serine, threonine, phenylalanine, tyrosine, and ornithine, suggesting that increased ovarian uptake of these amino acids contributes to anovulation.

If you struggle with anovulation, your body's handling of certain amino acids (serine, threonine, etc.) might be a key factor. This insight can help fertility specialists design more targeted treatments to support ovulation, addressing the metabolic root cause alongside hormonal therapies.

Obestatin, a peptide derived from the same gene as ghrelin, suppresses food intake and decreases body weight gain, acting as an anorexigenic counter-regulator to ghrelin.

Obestatin is a peptide derived from the same gene as ghrelin but has the opposite effect: it suppresses food intake and reduces body weight gain. It acts as a natural brake on appetite, balancing the hunger signals sent by ghrelin.

SIRT1 activation or overexpression increases PGC-1α gene transcription and mRNA expression in skeletal muscle cells through a mechanism involving direct binding to the PGC-1α promoter and interaction with the myogenic factor MyoD.

Skeletal muscle adaptation to metabolic demands involves SIRT1 regulating the expression of PGC-1α, a key master regulator of mitochondrial biogenesis. This process requires the interaction of SIRT1 with MyoD. While SIRT1 activators exist, their ability to increase PGC-1α transcription depends on the cellular environment and the presence of myogenic factors, suggesting that exercise (which induces MyoD and metabolic changes) is a critical co-factor for this pathway.

During the luteal phase of the menstrual cycle, healthy women exhibit significantly reduced plasma levels of amino acids and lipids, indicating an anabolic state driven by progesterone that increases metabolic vulnerability to conditions like PMS and PMDD.

If you experience PMS or PMDD symptoms, your body is likely in a metabolically demanding 'anabolic' state during the luteal phase (post-ovulation) where amino acids and lipids are being utilized for tissue preparation. This creates a window of vulnerability. While this paper does not prescribe a specific diet, it suggests that ensuring sufficient protein and nutrient intake during this phase may help support the body's increased metabolic demands and potentially mitigate symptoms.

Exposure to environmental metabolic disruptors (e.g., BPA, phthalates, TBT) during critical developmental windows (in utero, early childhood) permanently alters metabolic programming, increasing susceptibility to obesity, diabetes, and metabolic syndrome later in life.

Focus on reducing exposure to endocrine-disrupting chemicals, especially during pregnancy and early childhood. Avoid heating food in plastic containers, minimize use of canned goods with BPA linings, and reduce contact with thermal paper receipts. This is a preventative strategy to protect metabolic health.

Reducing exposure to environmental chemicals and improving nutrition during development can prevent obesity and metabolic diseases.

Use glass or stainless steel containers for food and water. Avoid heating food in plastic. Choose fresh foods over canned when possible. This is especially important for pregnant women and young children.

Mild hypoglycemia (a transient drop in circulating glucose) activates limbic-striatal brain regions and increases the desire for high-calorie foods, while euglycemia activates the medial prefrontal cortex to exert inhibitory control over food motivation.

If you experience strong cravings for junk food a few hours after eating, it may be due to a drop in blood sugar (hypoglycemia) rather than just the food itself. To reduce these cravings, consider strategies that prevent sharp drops in glucose, such as eating smaller, more frequent meals or choosing foods that stabilize blood sugar, especially if you are in an environment with lots of food cues.

Obese individuals lack the prefrontal cortical activation seen in non-obese individuals during euglycemia, resulting in a loss of glucose-linked inhibitory control over food motivation.

For obese individuals, the brain's natural 'brake' on food desire (mediated by the prefrontal cortex in response to normal blood sugar) may be less effective. This suggests that relying solely on willpower during normal eating times might be biologically harder, and strategies to stabilize blood sugar or reduce food cues are particularly important.

Exenatide (2 mg once weekly) significantly reduces alcohol cue reactivity in the ventral striatum and septal area in patients with Alcohol Use Disorder, but does not significantly reduce heavy drinking days in the general AUD population.

Exenatide, a weekly injection used for diabetes and obesity, changes how the brain responds to alcohol cues in addicted individuals, potentially reducing the 'pull' of drinking triggers. However, this neurobiological change did not automatically lead to fewer heavy drinking days for most patients in this study. It suggests that while the drug modifies reward processing, it may not be sufficient as a standalone treatment for reducing actual alcohol consumption in the general AUD population without additional behavioral support.

In obesity, elevated saturated fatty acids and proinflammatory cytokines activate JNK and IKK kinases, which phosphorylate insulin receptor substrate (IRS) on inhibitory serine residues, thereby blocking PI3K/Akt signaling and causing insulin resistance.

If you have excess body fat, your cells are likely resisting insulin due to inflammatory signaling triggered by fats and cytokines. This isn't permanent damage; it's a reversible signaling block. Reducing caloric excess and saturated fat intake can lower the metabolic stress that triggers this inflammatory kinase activity, potentially restoring insulin sensitivity.

Roux-en-Y gastric bypass (RYGBP) accelerates exogenous glucose appearance and enhances postprandial GLP-1 and PYY secretion compared to gastric banding (GB) and controls, leading to earlier and higher insulin peaks and faster glucose clearance.

For individuals undergoing Roux-en-Y gastric bypass, the procedure triggers a rapid release of gut hormones (GLP-1, PYY) and faster glucose absorption, which leads to a stronger and earlier insulin response. This hormonal shift helps clear glucose from the blood faster than in non-surgical individuals or those with gastric banding, contributing to improved glucose control even before significant weight loss occurs.

Gastric bypass (RYGBP) leads to enhanced postprandial suppression of ghrelin and increased PYY secretion compared to gastric banding and controls, which may contribute to reduced food intake.

Roux-en-Y gastric bypass increases the secretion of PYY and enhances the suppression of ghrelin after eating. These hormonal changes are associated with reduced food intake and may help patients feel fuller sooner and eat less compared to those who undergo gastric banding or no surgery.

Obesity is associated with 'leptin resistance,' where high circulating levels of leptin fail to produce expected anorexigenic effects due to receptor over-stimulation and impaired transport across the blood-brain barrier.

In obesity, your body produces plenty of the satiety hormone leptin, but your brain stops listening to it (leptin resistance). Simply having high leptin doesn't help you lose weight. Future treatments aim to bypass this resistance rather than just adding more hormone.

Gut hormones including GLP-1, PYY, and OXM are anorexigenic (appetite-suppressing) and are released in higher amounts after GI surgery, contributing to weight loss, whereas Ghrelin (orexigenic) levels are often reduced.

Your gut releases hormones like GLP-1 and PYY that tell your brain you are full. GI surgery works by boosting these hormones. New medications mimic this effect to help you lose weight without surgery.

Ectopic fat accumulation in visceral, hepatic, and pericardial depots acts as an active endocrine organ that promotes cardiovascular disease through insulin resistance, systemic inflammation, and oxidative stress, independent of overall body mass index.

Your weight on the scale is less important than where your fat is stored. Even if you are lean, excess fat around your organs (liver, heart, abdomen) can drive heart disease risk through inflammation and insulin resistance. Focus on metabolic health markers rather than just BMI.

Nonalcoholic fatty liver disease (NAFLD) is an independent predictor of incident cardiovascular events, driven by hepatic insulin resistance and systemic inflammation.

Fatty liver is not just a liver problem; it significantly increases your risk of heart disease and stroke, independent of your weight. Managing liver fat is crucial for cardiovascular health.